Racura Oncology (ASX:RAC) ROC (Joel Greenblatt) %: -368,150.00% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:RAC Racura Oncology Ltd ASX:RAC
28 GF Score
Price A$2.14
! 1 Warning Sign
View Full Analysis

What is Racura Oncology ROC (Joel Greenblatt) %?

Racura Oncology ASX:RAC -3.17% 28 ROC (Joel Greenblatt) % is -368,150.00% as of Jun. 2026. GuruFocus rates ASX:RAC with a GF Score™ of 28/100. The stock has 1 warning sign investors should review. Among 1,321 Biotechnology companies, Racura Oncology ranks worse than 99.47% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Racura Oncology's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was -368,150.00%.

The historical rank and industry rank for Racura Oncology's ROC (Joel Greenblatt) % or its related term are showing as below:

ASX:RAC' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -334350   Med: -1939.06   Max: -1099.51
Current: -334350

During the past 11 years, Racura Oncology's highest ROC (Joel Greenblatt) % was -1099.51%. The lowest was -334350.00%. And the median was -1939.06%.

ASX:RAC's ROC (Joel Greenblatt) % is ranked worse than
99.47% of 1321 companies
in the Biotechnology industry
Industry Median: -307.32 vs ASX:RAC: -334350.00

Racura Oncology's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Racura Oncology  (ASX:RAC) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Racura Oncology ROC (Joel Greenblatt) % Related Terms


Racura Oncology ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Racura Oncology's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Racura Oncology ROC (Joel Greenblatt) % Chart

Racura Oncology Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,939.06 0.00 0.00 0.00 -334,350.00

Racura Oncology Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -453.08 0.00 0.00 0.00 -368,150.00

ASX:RAC vs VRTX, REGN, MRNA: ROC (Joel Greenblatt) % Comparison

For the Biotechnology subindustry, Racura Oncology's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Racura Oncology ROC (Joel Greenblatt) % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Racura Oncology's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Racura Oncology's ROC (Joel Greenblatt) % falls into.


ASX:RAC
28GF Score
Racura Oncology Ltd ASX:RAC
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Racura Oncology ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.032 + 0 + 0.256) - (0.972 + 0 + 0.184)
=-0.868

Working Capital(Q: Jun. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.24299999999999) - (1.368 + 0 + 0.247)
=-1.372

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Racura Oncology for the quarter that ended in Jun. 2026 can be restated as:

ROC (Joel Greenblatt) %(Q: Jun. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Jun. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-14.726/( ( (0 + max(-0.868, 0)) + (0.004 + max(-1.372, 0)) )/ 1 )
=-14.726/( ( 0 + 0.004 )/ 1 )
=-14.726/0.004
=-368,150.00 %

Note: The EBIT data used here is two times the semi-annual (Jun. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of -368,150.00% mean?
Racura Oncology (ASX:RAC) has a ROC (Joel Greenblatt) % of -368,150.00% as of Jun. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Racura Oncology and its competitors. According to the industry distribution chart, Racura Oncology ranks #1314 out of 1321 companies in the Biotechnology industry, placing it in the top 99.5%.
Is Racura Oncology's ROC (Joel Greenblatt) % too high?
Racura Oncology's current ROC (Joel Greenblatt) % is -368,150.00%. Based on the distribution chart, Racura Oncology ranks #1314 out of 1321 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Racura Oncology has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Racura Oncology's ROC (Joel Greenblatt) % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Racura Oncology ranks #1314 out of 1321 companies for ROC (Joel Greenblatt) %. This places Racura Oncology in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Racura Oncology and its competitors. Racura Oncology's current ROC (Joel Greenblatt) % is -368,150.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Racura Oncology stock overvalued right now?
Racura Oncology (ASX:RAC) has a current ROC (Joel Greenblatt) % of -368,150.00%. The current ROC (Joel Greenblatt) % is -368,150.00%. Racura Oncology's overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Racura Oncology (ASX:RAC), the current ROC (Joel Greenblatt) % is -368,150.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Racura Oncology Business Description

Other Exchanges FN3:Germany
Address 1 Macquarie Place, Level 36, Gateway, Sydney, NSW, AUS, 2000
Racura Oncology Ltd is a developer of an oncology therapeutics platform designed to develop targeted cancer treatments. The company offers precision oncology drug development, biomarker-driven research, and cancer metabolism therapies, enabling healthcare providers and cancer patients to access targeted treatment options with improved therapeutic outcomes.
28GF Score

Get the complete analysis for ASX:RAC

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.14
Price